Research update from Dr. Bruce Lamb, 2013 CART Grant Recipient:
Dr. Bruce Lamb and colleagues from Cleveland Clinic’s Lerner Research Institute demonstrate the true role of TREM2 in AD in study published in The Journal of Experimental Medicine.
Previously thought to protect against Alzheimer’s, Dr. Lamb has discovered that TREM2 actually promotes the disease.
Deleting the TREM2 receptor in mice decreased plaque formation, reduced brain inflammation, and improved the survival of neurons. This protection was associated with fewer infiltrating macrophages. Macrophages lacking TREM2 were apparently better at engulfing beta-amyloid aggregates, suggesting that they might assist in the brain clean-up effort.
Although additional studies are needed to clarify the exact mechanism of TREM2’s action in AD, these results suggest that toning down the receptor’s activity may help put a stop to neurodegeneration in AD patients.read more
Looking for Fast Facts on The CART Fund? The October 2014 CART Fast Facts sheet is now available! Download your copy now!read more
Looking for the latest CART news and information? The September 2014 CART Newsletter is now available! Download your copy now!read more
On May 6, 2014, at the annual meeting of The CART Fund, Nigel J. Cairns, PhD, FRCPath, Professor, Department of Neurology, Washington University School of Medicine, St. Louis, MO was awarded a CART Grant in the amount of $250,000.
Although we have learned a great deal about the biology of Alzheimer’s in recent years there is still no effective treatment. Dr. Cairns and colleagues plan to use the CART award to investigate a promising new molecule to see if it can slow down or stop the damage caused to nerve cells by the disease. […]read more